---
figid: PMC3779382__328f6
figlink: /pmc/articles/PMC3779382/figure/F6/
number: Figure 6
caption: Therapeutic modulation of EBV infection and associated signaling pathways.
  Strategies to inactivate EBV infection or EBV-associated oncogenic pathways have
  been explored in lymphoma cells. Many therapeutic targets have been identified.
  (1) Conventional chemotherapeutic agents or radiation target DNA. (2) Different
  strategies disrupting miRNAs can be offered. (3) EBV-specific cytotoxic T cells
  are engineered and reinfused to patients as immunoregulatory therapy approach. (4)
  Lytic cycle of EBV is induced by a couple of agents, and antiherpetic agents targeting
  virus in lytic cycle are added. Agents targeting the (5) NF-κB pathway, (6), PI3K/Akt
  pathway, (7) PKC pathway, or (8) MAPK pathway can be tried. Monoclonal antibodies,
  Brentuximab vedotin and Rituximab, are available targeting for (9) CD30 and (10)
  CD20, respectively.
pmcid: PMC3779382
papertitle: EBV-positive diffuse large B-cell lymphoma of the elderly.
reftext: Chi Young Ok, et al. Blood. 2013 Jul 18;122(3):328-340.
pmc_ranked_result_index: '11329'
pathway_score: 0.9204608
filename: 328f6.jpg
figtitle: Therapeutic modulation of EBV infection and associated signaling pathways
year: '2013'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3779382__328f6.html
  '@type': Dataset
  description: Therapeutic modulation of EBV infection and associated signaling pathways.
    Strategies to inactivate EBV infection or EBV-associated oncogenic pathways have
    been explored in lymphoma cells. Many therapeutic targets have been identified.
    (1) Conventional chemotherapeutic agents or radiation target DNA. (2) Different
    strategies disrupting miRNAs can be offered. (3) EBV-specific cytotoxic T cells
    are engineered and reinfused to patients as immunoregulatory therapy approach.
    (4) Lytic cycle of EBV is induced by a couple of agents, and antiherpetic agents
    targeting virus in lytic cycle are added. Agents targeting the (5) NF-κB pathway,
    (6), PI3K/Akt pathway, (7) PKC pathway, or (8) MAPK pathway can be tried. Monoclonal
    antibodies, Brentuximab vedotin and Rituximab, are available targeting for (9)
    CD30 and (10) CD20, respectively.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - MAPK14
  - NFKB1
  - PIK3R4
  - MAPK9
  - MDM2
  - MAPK13
  - PIK3R5
  - PIK3CA
  - TNFRSF8
  - MAPK12
  - MAPK3
  - PRKCI
  - PRKD3
  - PRKCE
  - MAPK10
  - PIK3CD
  - PRKCG
  - BCR
  - PRKCH
  - MTOR
  - PIK3R3
  - PRKCA
  - MS4A1
  - TP53
  - PRKCQ
  - MAPK8
  - AKT3
  - PIK3R6
  - PIK3CG
  - AKT2
  - MAPK11
  - PRKCD
  - PIK3CB
  - AKT1
  - PRKCB
  - PRKCZ
  - 5-Azacytidine
  - Doxorubicin
  - Phorbol ester
  - Sodium butyrate
  - Cancer
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: NF-KB/p65
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: CD30
  symbol: CD30
  source: hgnc_prev_symbol
  hgnc_symbol: TNFRSF8
  entrez: '943'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: BCR
  symbol: BCR
  source: hgnc_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PI3K/MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: CD20
  symbol: CD20
  source: hgnc_prev_symbol
  hgnc_symbol: MS4A1
  entrez: '931'
- word: P53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
chemicals:
- word: 5-Azacytidine
  source: MESH
  identifier: D001374
- word: Doxorubicin
  source: MESH
  identifier: D004317
- word: Phorbol ester
  source: MESH
  identifier: D010703
- word: Sodium butyrate
  source: MESH
  identifier: D020148
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
